Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
10 12 2019
Historique:
entrez: 11 12 2019
pubmed: 11 12 2019
medline: 24 12 2019
Statut: ppublish

Résumé

An abdominal aortic aneurysm (AAA) is typically defined as aortic enlargement with a diameter of 3.0 cm or larger. The prevalence of AAA has declined over the past 2 decades among screened men 65 years or older in various European countries. The current prevalence of AAA in the United States is unclear because of the low uptake of screening. Most AAAs are asymptomatic until they rupture. Although the risk for rupture varies greatly by aneurysm size, the associated risk for death with rupture is as high as 81%. To update its 2014 recommendation, the USPSTF commissioned a review of the evidence on the effectiveness of 1-time and repeated screening for AAA, the associated harms of screening, and the benefits and harms of available treatments for small AAAs (3.0-5.4 cm in diameter) identified through screening. This recommendation applies to asymptomatic adults 50 years or older. However, the randomized trial evidence focuses almost entirely on men aged 65 to 75 years. Based on a review of the evidence, the USPSTF concludes with moderate certainty that screening for AAA in men aged 65 to 75 years who have ever smoked is of moderate net benefit. The USPSTF concludes with moderate certainty that screening for AAA in men aged 65 to 75 years who have never smoked is of small net benefit. The USPSTF concludes that the evidence is insufficient to determine the net benefit of screening for AAA in women aged 65 to 75 years who have ever smoked or have a family history of AAA. The USPSTF concludes with moderate certainty that the harms of screening for AAA in women aged 65 to 75 years who have never smoked and have no family history of AAA outweigh the benefits. The USPSTF recommends 1-time screening for AAA with ultrasonography in men aged 65 to 75 years who have ever smoked. (B recommendation) The USPSTF recommends that clinicians selectively offer screening for AAA with ultrasonography in men aged 65 to 75 years who have never smoked rather than routinely screening all men in this group. (C recommendation) The USPSTF recommends against routine screening for AAA with ultrasonography in women who have never smoked and have no family history of AAA. (D recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AAA with ultrasonography in women aged 65 to 75 years who have ever smoked or have a family history of AAA. (I statement).

Identifiants

pubmed: 31821437
pii: 2757234
doi: 10.1001/jama.2019.18928
doi:

Types de publication

Journal Article Practice Guideline Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2211-2218

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : SummaryForPatientsIn
Type : CommentIn

Auteurs

Douglas K Owens (DK)

Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
Stanford University, Stanford, California.

Karina W Davidson (KW)

Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York.

Alex H Krist (AH)

Fairfax Family Practice Residency, Fairfax, Virginia.
Virginia Commonwealth University, Richmond.

Michael J Barry (MJ)

Harvard Medical School, Boston, Massachusetts.

Michael Cabana (M)

University of California, San Francisco.

Aaron B Caughey (AB)

Oregon Health & Science University, Portland.

Chyke A Doubeni (CA)

Mayo Clinic, Rochester, Minnesota.

John W Epling (JW)

Virginia Tech Carilion School of Medicine, Roanoke.

Martha Kubik (M)

Temple University, Philadelphia, Pennsylvania.

C Seth Landefeld (CS)

University of Alabama at Birmingham.

Carol M Mangione (CM)

University of California, Los Angeles.

Lori Pbert (L)

University of Massachusetts Medical School, Worcester.

Michael Silverstein (M)

Boston University, Boston, Massachusetts.

Melissa A Simon (MA)

Northwestern University, Evanston, Illinois.

Chien-Wen Tseng (CW)

University of Hawaii, Honolulu.
Pacific Health Research and Education Institute, Honolulu, Hawaii.

John B Wong (JB)

Tufts University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH